Heterogeneous Cell Therapy FCR001 For The Treatment of Severe Sclerotic Disease: IND Approved by FDA
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Scleropathy, also known as systemic sclerosis (SSc), is divided into localized types of skin-only symptoms that do not invade the visceral system or systemic sclerosis that will invade the visceral systemThis is a systemic autologousimmunedisease characterized by restrictive or diffuse skin thickening, hardening and visceral fibrosisThe lesions are characterized by significant growth of skin fibroblasts, increased collagen fibers and changes in the appearance of onion skinskin, resulting in hardening of the skin,blood vesselsischemia, in addition to skin suffering, it can also affect the internal organs (heart, lung anddigestiveThe incidence rate for women is three to four times that of menbiotech company Talaris recently announced that the U.SFDAhas approved the company's research new drug application (IND) for the new cell therapy FCR001 treatment of diffuse systemic sclerosis (SSc) I/IIa clinical trialScott Requadt, chief executive of Talaris, said: "Patients with diffuse SSc are in great need of safe and effective treatment optionsWe believe that FCR001 may represent a new way of treating this serious disease."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
